利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.035 秒)

    Sustained release intraocular implants and methods for preventing retinal dysfunction
    2.
    发明申请
    Sustained release intraocular implants and methods for preventing retinal dysfunction 审中-公开
    持续释放眼内植入物和预防视网膜功能障碍的方法

    公开(公告)号：US20050244506A1

    公开(公告)日：2005-11-03

    申请号：US11118519

    申请日：2005-04-29

    申请人： James Burke ,  Patrick Hughes ,  Werhner Orilla ,  Ton Lin ,  Maria Escobar ,  Glenn Huang ,  Kai-Ming Zhang ,  Larry Wheeler ,  Rosy Donn

    发明人： James Burke ,  Patrick Hughes ,  Werhner Orilla ,  Ton Lin ,  Maria Escobar ,  Glenn Huang ,  Kai-Ming Zhang ,  Larry Wheeler ,  Rosy Donn

    IPC分类号： A61F2/02 ,  A61K9/00 ,  A61K9/14 ,  A61K31/498

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.

    摘要翻译： 生物相容的眼内微球和植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以治疗或防止一种或多种眼部病症的发生，以减少眼部疾病如眼部神经感觉障碍等的一种或多种症状，以增强正常的视网膜功能和/ 或降低眼内压。

    Sustained release intraocular implants and methods for preventing retinal dysfunction
    3.
    发明申请
    Sustained release intraocular implants and methods for preventing retinal dysfunction 有权
    持续释放眼内植入物和预防视网膜功能障碍的方法

    公开(公告)号：US20050244479A1

    公开(公告)日：2005-11-03

    申请号：US10837143

    申请日：2004-04-30

    申请人： Glenn Huang ,  James Burke ,  Patrick Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry Wheeler ,  Rosy Donn

    发明人： Glenn Huang ,  James Burke ,  Patrick Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry Wheeler ,  Rosy Donn

    IPC分类号： A61F2/02 ,  A61K9/00 ,  A61K9/14 ,  A61K31/498

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

    摘要翻译： 生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以防止发生一种或多种眼部病症，或者减少眼部疾病如眼睛神经感觉障碍等的一种或多种症状。

    Agents and methods for enhancing photodynamic therapy
    8.
    发明申请
    Agents and methods for enhancing photodynamic therapy 审中-公开
    用于增强光动力疗法的药剂和方法

    公开(公告)号：US20060223750A1

    公开(公告)日：2006-10-05

    申请号：US11096886

    申请日：2005-04-01

    申请人： James Burke ,  Elizabeth Syage ,  Michael Garst ,  Larry Wheeler

    发明人： James Burke ,  Elizabeth Syage ,  Michael Garst ,  Larry Wheeler

    IPC分类号： A61K38/17 ,  A61K38/05 ,  A61K31/739 ,  A61K31/409 ,  A61K31/555 ,  C07K14/74 ,  C07K5/06

    CPC分类号： A61K41/0071 ,  A61K41/0057 ,  A61K47/543 ,  A61K47/61

    摘要： A chemical conjugate for administration to a patient undergoing photodynamic therapy includes a photoactive compound coupled to a leakage reducing agent that is structured to reduce leakage of the photoactive compound from a patient's vasculature. The leakage reducing agent may be a bulking agent to reduce, for example, sterically reduce, the permeability of the photoactive compound through the blood vessel, or it may be a ligand that binds to endothelial cells of a patient's choriocapillaries. The conjugate may be used in methods of reducing secondary damage associated with photodynamic therapy.

    摘要翻译： 用于给予经历光动力治疗的患者的化学共轭物包括偶联到减漏剂的光活性化合物，其被构造为减少光活性化合物从患者脉管系统的泄漏。 渗漏还原剂可以是填充剂，以减少（例如）空间地降低光活性化合物通过血管的渗透性，或者它可以是与患者绒毛膜毛细血管的内皮细胞结合的配体。 缀合物可用于减少与光动力疗法相关的次级损伤的方法。